Caris Life Sciences is a privately held biotechnology company based in Irving, Texas, United States. It was founded in 2008 with a vision to revolutionize precision medicine by providing comprehensive molecular profiling services. The company's headquarters is situated in Irving and serves as its primary operational center.

Caris Life Sciences offers a range of products and services focused on precision medicine. Its flagship offering is the Caris Molecular Intelligence® platform, which combines comprehensive tumor profiling with clinical outcomes database to provide physicians with actionable insights for personalized cancer treatment. The platform analyzes DNA, RNA, and proteins of a patient's tumor sample to identify the most suitable treatment options and clinical trials available.

This molecular profiling service is utilized by oncologists worldwide to make informed treatment decisions. On a global scale, Caris Life Sciences has established partnerships with healthcare providers, research organizations, and pharmaceutical companies. It has collaborations with leading cancer centers such as UCLA Jonsson Comprehensive Cancer Center, Sarah Cannon Research Institute, and Mayo Clinic.

These collaborations ensure the continued development and validation of its molecular profiling services. In terms of market position, Caris Life Sciences is recognized as a leader in the field of precision medicine. It has a strong global presence and its molecular profiling services are widely used by oncologists across various regions.

While specific sales figures are not publicly disclosed, the company's emphasis on precision medicine and its partnerships with prestigious institutions contribute to its competitive standing. In recent years, Caris Life Sciences has expanded its offerings to include liquid biopsy tests for monitoring cancer treatment response and detecting minimal residual disease. This expansion highlights the company's commitment to developing innovative solutions for personalized cancer care.

As of the latest information available, Caris Life Sciences continues to advance precision medicine through its molecular profiling services. The company is committed to improving patient outcomes by providing oncologists with scientifically robust information for personalized cancer treatment decisions